{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:12:30Z","timestamp":1795043550005,"version":"4.10.2"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BridgeBio Inc."}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46\u20130.72) at month 42 based on a stratified Cox proportional hazards model (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with hazard ratios of 0.64 (95% CI, 0.47\u20130.88) and 0.53 (95% CI, 0.41\u20130.69), respectively, at month 42. Treatment effects for NT-proBNP and 6-minute walk distance also favored continuous acoramidis. On initiation of open-label acoramidis in the placebo-to-acoramidis arm, there was a prompt increase in serum transthyretin. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score was well preserved in continuous-acoramidis participants compared with the placebo-to-acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Early initiation and continuous use of acoramidis in the ATTRibute-CM study through month 42 of the ongoing OLE study were associated with sustained clinical benefits in a contemporary transthyretin amyloid cardiomyopathy cohort, with no clinically important safety issues newly identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>REGISTRATION:<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique identifier: NCT04988386.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.124.072771","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T11:09:06Z","timestamp":1731928146000},"page":"601-611","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":74,"title":["Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial"],"prefix":"10.1161","volume":"151","clinical-trial-number":[{"clinical-trial-number":"nct04988386","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-0248","authenticated-orcid":true,"given":"Daniel P.","family":"Judge","sequence":"first","affiliation":[{"name":"Division of Cardiology, Medical University of South Carolina, Charleston (D.P.J.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":true,"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, Royal Free Hospital, UK (J.D.G., M.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-3691","authenticated-orcid":true,"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Palo Alto, CA (K.M.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-4203","authenticated-orcid":true,"given":"Amrut V.","family":"Ambardekar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Consortium for Fibrosis Research &amp; Translation, University of Colorado Anschutz Medical Campus, Aurora (A.V.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-0732","authenticated-orcid":true,"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, IT (F.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":true,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, Royal Free Hospital, UK (J.D.G., M.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":true,"given":"Pablo","family":"Garc\u00eda-Pav\u00eda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda and Centro Nacional de Investigaciones Cardiovasculares, Madrid, ES (P.G.-P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-3196","authenticated-orcid":true,"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (J.L.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-4440","authenticated-orcid":true,"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, OH (M.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":true,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Oregon Health &amp; Science University, Portland (A.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-2122","authenticated-orcid":true,"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[{"name":"Department of Transplant, Mayo Clinic, Jacksonville, FL (J.N.-N.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-700X","authenticated-orcid":true,"given":"Laura","family":"Obici","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, IT (L.O.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Hvitfeldt Poulsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, DK (S.H.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-7881","authenticated-orcid":true,"given":"Nitasha","family":"Sarswat","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Chicago Medicine, IL (N.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Shah","sequence":"additional","affiliation":[{"name":"Pauley Heart Center, Department of Cardiology, Virginia Commonwealth University, Richmond (K.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1425-6536","authenticated-orcid":true,"given":"Prem","family":"Soman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Pittsburgh Medical Center, PA (P.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-0761","authenticated-orcid":true,"given":"Ted","family":"Lystig","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Cao","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wang","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia","family":"Pecoraro","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tamby","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Katz","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sinha","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1250-5239","authenticated-orcid":true,"given":"Jonathan C.","family":"Fox","sequence":"additional","affiliation":[{"name":"BridgeBio Pharma, Inc, San Francisco, CA (T.L., X.C., K.W., M.L.P., J.-F.T., L.K., U.S., J.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":true,"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, NY (M.S.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.67"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1262"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00817"},{"key":"e_1_3_3_12_2","unstructured":"Judge DP Cappelli F Fontana M Garc\u00eda-Pav\u00eda P Gibbs S Grogan M Hanna M Masri A Maurer MS Obici L et al. Acoramidis improves clinical outcomes in transthyretin amyloid cardiomyopathy patients. Presented at: 2023 American Heart Association Scientific Sessions; November 10\u201313 2023; Philadelphia PA."},{"key":"e_1_3_3_13_2","unstructured":"Judge DP Alexander KM Cappelli F Fontana M Garc\u00eda-Pav\u00eda P Gibbs S Grogan M Hanna M Masri A Maurer MS et al. Acoramidis improves clinical outcomes in patients with transthyretin amyloid cardiomyopathy: post hoc recurrent event analyses of ATTRibute-CM. Presented at: 2024 Heart Failure Society of America Annual Scientific Meeting; September 27\u201330 2024; Atlanta GA."},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Maurer MS Masri A Judge DP Cappelli F Fontana M Grogan M Hanna M Garc\u00eda-Pav\u00eda P Du J Siddhanti S et al. Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension. Presented at: 2024 European Society of Cardiology Congress; August 30\u2013September 2 2024 London UK.","DOI":"10.1093\/eurheartj\/ehae666.2088"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.989"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.124.072771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:00:38Z","timestamp":1741010438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.124.072771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,3,4]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.124.072771"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.124.072771","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"2024-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}